AGMB (AgomAb Therapeutics NV) EBITDA Margin %: 0.00% (As of Dec. 2025)


AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $13.08
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV EBITDA Margin %?

AgomAb Therapeutics NV AGMB +0.85% 14 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, AgomAb Therapeutics NV ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. AgomAb Therapeutics NV's EBITDA for the three months ended in Dec. 2025 was $-20.64 Mil. AgomAb Therapeutics NV's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, AgomAb Therapeutics NV's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

AgomAb Therapeutics NV  (NAS:AGMB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

AgomAb Therapeutics NV EBITDA Margin % Related Terms

AgomAb Therapeutics NV EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV EBITDA Margin % Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00 0.00 0.00

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25
EBITDA Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

AGMB vs DNA, ACRS, RLMD: EBITDA Margin % Comparison

For the Biotechnology subindustry, AgomAb Therapeutics NV's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AgomAb Therapeutics NV EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where AgomAb Therapeutics NV's EBITDA Margin % falls into.


AGMB
14GF Score
AgomAb Therapeutics NV AGMB
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AgomAb Therapeutics NV EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

AgomAb Therapeutics NV's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-72.913/0
= %

AgomAb Therapeutics NV's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-20.636/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
AgomAb Therapeutics NV (AGMB) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AgomAb Therapeutics NV and its competitors. According to the industry distribution chart, AgomAb Therapeutics NV ranks #999999 out of 939 companies in the Biotechnology industry.
Is AgomAb Therapeutics NV's EBITDA Margin % too high?
AgomAb Therapeutics NV's current EBITDA Margin % is 0.00%. Based on the distribution chart, AgomAb Therapeutics NV ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's EBITDA Margin % compare to DNA and ACRS?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #999999 out of 939 companies for EBITDA Margin %. This places AgomAb Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.08
Price